Brief: Neuren Pharmaceuticals Says Rett Syndrome NDA Accepted For Priority Review By FDA
13/09/2022 02:27
Sept 13 (Reuters) - Neuren Pharmaceuticals Ltd NEU.AX :
* RETT SYNDROME NEW DRUG APPLICATION ACCEPTED FOR PRIORITY
REVIEW
BY FDA
Source text for Eikon: ID:nASX3Qrcs9
Further company coverage: NEU.AX
Recent news on Neuren Pharmaceuticals
See all newsAustralia's Neuren set for weekly gain on FDA nod, drug forecast upgrade
Australia's Neuren Pharmaceuticals gains on upbeat FY trofinetide earnings outlook
Australia's Neuren Pharma rises as US FDA grants orphan tag for NNZ-2591
Strong partner sales propel Neuren Pharmaceuticals to top of Australia benchmark
Brief: Neuren Pharmaceuticals Says DAYBU Recommended For Approval In European Union